**COVID-END partners coordination call**

Notes from 15 April 2021

https://zoom.us/j/6163788736

1. **INTRODUCTIONS**
   a. Jeremy welcomed partners to the call

2. **REVIEW OF COVID-END ACTION ITEMS**
   a. Jeremy pointed partners to the notes from 1 April (see attachment 2)

3. **COVID-END NETWORK UPDATES**
   a. Jeremy provided a brief update on the status of the global commission
   b. Jeremy invited partners to add to our running list of current methodological issues related to the COVID-19 evidence response
      i. What constitutes a living evidence synthesis (or what parameters of living evidence syntheses that should be explicitly documented)?
      ii. How to approach the quick and clean enough appraisal of guidelines?
      iii. Whether to include ‘old’ studies about COVID-19 in evidence syntheses? (e.g., because of the emergence of variants and vaccines, with the latter being important context to survey data about vaccine confidence and uptake)?
      iv. How to engage citizen partners in rapid syntheses? (note that Maureen Smith has shared an annotated list of resources with the secretariat for addition to the website and she indicated that the citizen partners could contribute to a webinar once they have participated in several ultra-rapid syntheses)
      v. How to fill the gap left between what existing evidence syntheses are addressing and what decision-makers are asking?
      vi. **ACTION:** Partners to submit additional suggestions and notify Maureen Dobbins and Laurenz Langer if they would be willing to post to the listserv and/or contribute to a webinar on one or more of the above topics
   c. COVID-END anniversary
      i. Jeremy reminded partners that we recently passed the 12 months mark for COVID-END and he introduced the idea of tentatively planning a webinar to reflect on lessons learned over the 12-15 months into COVID-END response
      ii. **ACTION:** Maureen to slot COVID-END in for an anniversary webinar in May or June

4. **PARTNER PROFILE**
   a. Jeremy welcomed two partners who provided an overview of their work supporting COVID-19 response
      i. Alfonso Iorio presented on behalf of McMaster PLUS
      ii. Nikita Burke presented on behalf of Evidence Synthesis Ireland
b. John asked whether any partners had any experience with critically appraising modeling studies (and if so, for what types of modeling studies), and Alfonso and Elie pointed to three resources:
   i. GRADE approach to assessing the certainty of modeled evidence ([https://www.jclinepi.com/article/S0895-4356(20)31103-3/abstract](https://www.jclinepi.com/article/S0895-4356(20)31103-3/abstract))
   ii. Prediction models for diagnosis and prognosis ([https://www.bmj.com/content/369/bmj.m1328](https://www.bmj.com/content/369/bmj.m1328))
   iii. Project website focused on prediction models ([https://www.covprecise.org/](https://www.covprecise.org/))

5. NEWS AND INITIATIVES OF INTEREST TO PARTNERS

   a. Jeremy pointed partners to Evidence Synthesis Ireland’s [Priority III study](https://www.evidenceireland.org/)
      i. Online survey asking patient and public representatives, reviewers, researchers, clinicians and policymakers to select the 10 questions that are most important for future research to address
      ii. Survey can be found [here](https://www.evidenceireland.org/)

   b. Jeremy also pointed partners to ACTS COVID-19 Evidence to Guidance to Action Collaborative developing Living Evidence Guidance dashboards
      i. Dashboards leverage the [COVID-END inventory of best evidence syntheses](https://covid-end.com/) and offerings from several COVID-END partners
      ii. Input from COVID-END partners is welcomed to make the dashboards more helpful to users and to leverage pertinent evidence and guidance resources
      iii. See [here](https://covid-end.com/) for further details

6. ANY OTHER BUSINESS

   a. No other business